Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform
News Feb 15, 2013
ChemAxon has announced that Boehringer Ingelheim has chosen its chemistry software platform for multiple applications across research and development, supporting in-house activities and work with external collaboration partners.
ChemAxon technology will be used to store, search, calculate, and visualize chemical entities, properties and reactions, helping to streamline the progression from drug discovery to clinical candidate.
ChemAxon was chosen after an extensive evaluation process that built on dimensions such as ROI, performance, robustness, scalability and future development roadmap.
ChemAxon sets the standard in chemically-intelligent software for pharmaceutical R&D.
With a client list that includes all of the top 15 global pharma companies, the company continues to experience significant growth year on year.
Commenting on the agreement, Alex Drijver, CEO of ChemAxon said, “The adoption of ChemAxon technology by Boehringer Ingelheim further underlines our position as the platform of choice for R&D organizations planning their next-generation systems.”
It's easy to take a lot for granted. Scientists do this when they study stress, the force per unit area on an object. Scientists handle stress mathematically by assuming it to have symmetry, but new supercomputer simulations show that at the atomic level, material stress doesn't behave symmetrically. The findings could help scientists design new materials such as glass or metal that doesn't ice up.READ MORE
In late 2017 DeepMind introduced AlphaZero, a single system that taught itself from scratch how to master the games of chess, shogi (Japanese chess), and Go, beating a world-champion program in each case. Today, they announce the evalutation of AlphaZero, published in the journal Science, that confirms and updates those preliminary results.
7th Plant Genomics and Gene Editing Congress: Europe
Oct 10 - Oct 11, 2019